Welcome to our dedicated page for Aim Immunotech SEC filings (Ticker: AIMI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AIM ImmunoTech Inc. (AIMI/AIM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a smaller reporting biotechnology issuer focused on immuno-pharma therapeutics. AIM ImmunoTech files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements on Schedule 14A and other forms that document its financial condition, governance decisions and material events.
For investors tracking AIM ImmunoTech’s development-stage biotechnology business, the company’s periodic reports are central. The Form 10-K and Form 10-Q filings describe its status as a smaller reporting company, summarize its focus on therapeutics for cancers, immune disorders and viral diseases, and provide financial statements that reflect revenues and net losses consistent with a research-focused enterprise. A Form 12b-25 (Notification of Late Filing) for the quarter ended September 30, 2025 explains delays in completing the required review, outlines the expectation to file within the permitted extension period and describes anticipated changes in revenues, net loss and loss per share compared to prior-year periods.
AIM ImmunoTech also uses Form 8-K to report material events. Examples include furnishing a corporate presentation under Regulation FD, disclosing NYSE American notices of noncompliance with minimum stockholders’ equity requirements and the acceptance of a plan to regain compliance, and filing its Certificate of Incorporation as amended and restated as an exhibit. These current reports help investors understand exchange listing issues, governance documents and other significant developments beyond routine financial reporting.
Proxy statements on Schedule 14A, such as the definitive proxy for the 2025 Annual Meeting of Stockholders, provide detail on board elections, advisory votes on executive compensation, auditor ratification and the company’s use of scaled disclosure obligations as a smaller reporting company. Voting results for proposals, reported via Form 8-K, show how stockholders have voted on directors, compensation matters and the frequency of advisory votes.
On Stock Titan, AIM ImmunoTech’s filings are updated as they appear on EDGAR, and AI-powered tools summarize key points from lengthy documents such as 10-Ks, 10-Qs, 8-Ks and proxy statements. This helps users quickly identify information on topics such as financial performance trends, exchange compliance, governance decisions and material agreements, while still allowing access to the full original filings for detailed review. Form 4 insider transaction data, when filed, can also be monitored alongside these core disclosures to give a fuller picture of corporate activity.
AIM ImmunoTech Inc. furnished its January 2026 Corporate Presentation as an exhibit to this report. The presentation is provided under Regulation FD to share updated corporate information with the market and is designated as “furnished,” meaning it is not treated as filed for certain liability purposes under federal securities laws.
The company reiterates that the presentation may contain forward-looking statements about its drug candidate Ampligen®, including current and anticipated future activities in viral diseases, cancers, and immune-deficiency disorders. AIM emphasizes that significant additional testing and human clinical trials are required, results from animal studies may not predict human outcomes, and there is no assurance that ongoing or planned clinical trials will be successful, yield favorable data, or proceed as expected. The company directs readers to the risk factors in its latest annual and quarterly reports for a fuller discussion of risks.
AIM ImmunoTech Inc. held its 2025 annual meeting of stockholders on December 16, 2025. A quorum was present, with 1,144,383 of 2,764,188 common shares represented in person or by proxy.
Stockholders voted on four proposals. All director nominees were elected, with individual support ranging from 243,183 to 280,350 votes in favor. Stockholders also strongly supported retaining BDO USA, P.C. as independent registered public accounting firm for 2025, with 1,104,780 votes for and 29,754 against.
The non-binding advisory vote on executive compensation saw 193,668 votes for, 115,337 against, 2,505 abstentions and 833,173 broker non-votes. Although a majority of votes cast supported the pay package, it did not receive the required majority in voting power represented and entitled to vote, and therefore was not approved. In a separate advisory vote on frequency of say-on-pay, 284,856 votes favored annual votes, and the board decided to hold this vote every year.
AIM ImmunoTech Inc. reported another loss-making quarter while facing serious financial pressures and exchange-listing risks. For the three months ended September 30, 2025, revenue from clinical treatment programs was only $26,000, against operating expenses of $2.5 million, leading to an operating loss of $2.4 million and a net loss of $3.3 million. For the first nine months of 2025, the company recorded a net loss of $9.8 million, compared with $11.4 million a year earlier. Cash and cash equivalents were $2.3 million, while total assets were $5.5 million and total liabilities $11.6 million, resulting in a stockholders’ deficit of $6.1 million. A new warrant liability of $7.3 million was recorded after an August 2025 equity and warrant financing. Management states that recurring losses, a working capital deficit and sub-minimum equity raise substantial doubt about the company’s ability to continue as a going concern. AIM executed a 1-for-100 reverse stock split in June 2025 to address low trading prices, and its stock was reinstated on NYSE American, but it must lift stockholders’ equity to at least $6.0 million by June 11, 2026 to remain in compliance.
Aim ImmunoTech Inc. filed a notice that it will be late filing its Form 10-Q for the quarter ended September 30, 2025, citing delays in completing its review and the need for more time to compile and verify data. The company expects to file the report within the allowed extension period.
Preliminary figures for the three months ended September 30, 2025 show revenues of approximately $26,000, down from about $35,000 a year earlier, while net loss is expected to narrow to roughly $3,284,000 from about $3,700,000. For the nine-month period, revenue is expected to decrease to around $67,000 from about $125,000, with net loss improving to roughly $9,783,000 from about $11,353,000.
Net loss per share – basic and diluted – is expected to be about $(1.57) for the quarter versus $(6.00) a year earlier, and $(8.18) for the nine months versus $(21.00) in the prior-year period, indicating a smaller loss spread over the company’s share base.
AIM ImmunoTech Inc. launched an at-the-market offering of up to
The company notes non‑affiliate market value of approximately
AIM ImmunoTech Inc. reported that it filed its amended and restated Certificate of Incorporation as Exhibit 3.1(i). The updated certificate is consolidated through October 29, 2025 and supersedes prior exhibit pieces.
The filing lists exhibits under Item 9.01 and includes the Cover Page Inline XBRL file. AIM’s common stock trades on the NYSE American under the symbol AIM.
AIM ImmunoTech Inc. filed its definitive proxy for the 2025 Annual Meeting. The virtual meeting is set for December 16, 2025 at 11:00 a.m. Eastern Time. Stockholders of record at the close of business on October 24, 2025 may vote; shares outstanding and entitled to vote were 2,764,188 as of the record date.
The Board recommends voting FOR all five director nominees—Nancy K. Bryan, Thomas K. Equels, Ted D. Kellner, David I. Chemerow and William M. Mitchell—FOR ratification of BDO USA, P.C. as independent auditor for the fiscal year ending December 31, 2025, FOR approval, on an advisory basis, of named executive officer compensation, and selecting 1 YEAR for the frequency of future say‑on‑pay votes.
Directors will be elected by a plurality of votes cast; Proposals 2–4 require a majority in voting power of shares represented and entitled to vote. Quorum is 33 and 1/3% of shares entitled to vote. Proxies are being solicited by the Board; Sodali & Co. has been engaged to assist, for a fee of $20,000 plus expenses. AIM notes it is a smaller reporting company using scaled disclosures. Materials, including the 2024 Form 10‑K, are available via the company’s website and the SEC.
FAQ
What is the current stock price of Aim Immunotech (AIMI)?
What is the market cap of Aim Immunotech (AIMI)?
